Taking a sleep supplement? The new FDA warning you should know about

An FDA advisory committee voted against approving the sleep supplement Emideltide due to safety concerns, including its connection to the opioid system and potential for addiction. The decision prohibits pharmacies in the US from manufacturing it.

An FDA advisory committee voted against approving the use of the sleep supplement Emideltide (DSIP), a synthetic peptide marketed as a solution for deep and rapid sleep. The decision was made due to significant safety concerns, including a possible link to the brain's opioid system and potential for addiction. The FDA prohibits pharmacies in the US from manufacturing the supplement. Studies on its effectiveness, conducted mainly in the 1980s and 1990s, yielded mixed and contradictory results. Reported side effects include headaches, nausea, and low blood pressure. The article emphasizes that not every dietary supplement marketed as a health solution is safe or effective.